Symptomatic Intracranial Atherosclerotic Stenosis

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Symptomatic Intracranial Atherosclerotic Stenosis is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Unknown status3 · 75%

Recruiting1 · 25%

Clinical Trials

Trial Activity

Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome

Recruiting·NNanjing First Hospital, Nanjing Medical University·N/A·NCT05397405·180 enrolled

Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT06080256·80 enrolled

Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT05741086·80 enrolled

Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT06052020·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)